#1 Clinical Trials Search in Europe

Degarelix Acetate

Degarelix Acetate, also known as Firmagon, is a drug being studied in clinical trials for the treatment of prostate cancer. This article will discuss its use in combination with other treatments, its effects on testosterone levels, and its potential benefits for patients with prostate cancer. We’ll explore how this medication works and its role in androgen deprivation therapy (ADT), a common approach in managing prostate cancer.

Table of Contents

What is Degarelix Acetate?

Degarelix acetate, also known by its brand name Firmagon, is a medication used in the treatment of prostate cancer[1]. It belongs to a class of drugs called gonadotropin-releasing hormone (GnRH) receptor antagonists[2]. This medication is specifically designed to help manage prostate cancer by reducing the levels of testosterone in the body.

How Does Degarelix Acetate Work?

Degarelix acetate works by blocking the GnRH receptors in the body. This action leads to a decrease in the amount of testosterone produced[2]. Testosterone is a hormone that can fuel the growth of prostate cancer cells. By lowering testosterone levels, degarelix acetate helps to slow down or stop the growth of prostate cancer tumors.

Unlike some other prostate cancer treatments, degarelix acetate does not cause an initial surge in testosterone levels. This means it can quickly and reliably bring testosterone to what doctors call “castrate levels” – very low levels that help control the cancer[1].

What Conditions Does Degarelix Acetate Treat?

Degarelix acetate is primarily used to treat prostate cancer. It’s particularly useful in a treatment approach called androgen deprivation therapy (ADT)[1]. ADT is a way of treating prostate cancer by reducing the levels of male hormones (androgens) like testosterone in the body. This can help to slow down the growth of prostate cancer cells, which often rely on these hormones to grow.

How is Degarelix Acetate Administered?

Degarelix acetate is typically administered as a subcutaneous injection, which means it’s injected just under the skin. In clinical trials, it has been given in the following ways:

  • As a monthly depot injection for three months[1]
  • As three 80 mg subcutaneous injections, for a total dose of 240 mg, typically given about two weeks before a planned surgery for prostate cancer[2]

The exact dosage and schedule may vary depending on the individual patient’s needs and treatment plan.

Clinical Trials Involving Degarelix Acetate

Several clinical trials have been conducted to study the effectiveness of degarelix acetate in treating prostate cancer. Here are some key studies:

  1. A study (NCT01344564) aimed to determine if patients starting androgen deprivation therapy for prostate cancer could transition from degarelix acetate to another medication (leuprolide acetate) after an initial three-month period. The goal was to see if testosterone levels would remain at castrate levels during this transition[1].

  2. Another study (NCT01696877) investigated the use of degarelix acetate in combination with other treatments, including a prostate cancer vaccine called GVAX and a drug called cyclophosphamide. This study looked at patients with high-risk localized prostate cancer who were preparing to undergo surgery to remove their prostate glands[2].

Combination Therapy with Degarelix Acetate

Research is ongoing to explore how degarelix acetate can be combined with other treatments to potentially enhance its effectiveness. For example:

  • Combination with immunotherapy: Some studies are looking at combining degarelix acetate with treatments that boost the immune system’s ability to fight cancer. This includes vaccines like GVAX, which is designed to stimulate the immune system to attack prostate cancer cells[2].

  • Combination with other medications: Researchers have studied transitioning patients from degarelix acetate to other hormone therapies like leuprolide acetate, to see if the benefits of treatment can be maintained[1].

These combination approaches are still being studied to determine their safety and effectiveness. Patients should always discuss their treatment options with their healthcare provider to determine the best approach for their individual case.

Aspect Details
Drug Name Degarelix Acetate (Firmagon)
Drug Type Gonadotropin-releasing hormone (GnRH) receptor antagonist
Primary Use Androgen Deprivation Therapy (ADT) for prostate cancer
Mechanism of Action Decreases testosterone levels in the body
Administration Subcutaneous injections
Combination Therapies Studied with cyclophosphamide, GVAX vaccine, and in transition to leuprolide acetate
Key Study Objectives Assess testosterone suppression, immune responses, safety, and effectiveness
Outcome Measures Testosterone levels, T-cell infiltration, PSA levels, pathological responses

FAQ

  • What is Degarelix Acetate and how does it work? Degarelix Acetate, also known as Firmagon, is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by decreasing the amount of testosterone in the body, which prostate cancer tumors need to grow. This medication is used as part of androgen deprivation therapy (ADT) for prostate cancer treatment.
  • How is Degarelix Acetate administered in clinical trials? In the clinical trials discussed, Degarelix Acetate is typically administered as subcutaneous injections. For example, in one study, patients received three 80 mg injections for a total dose of 240 mg, given about two weeks before surgery.
  • Can Degarelix Acetate be used in combination with other treatments? Yes, the clinical trials explore using Degarelix Acetate in combination with other treatments. For instance, one study investigates its use alongside cyclophosphamide and a prostate cancer vaccine called GVAX. Another trial examines transitioning from Degarelix Acetate to another medication called leuprolide acetate.
  • What are the main goals of these clinical trials using Degarelix Acetate? The main goals of these trials include: 1) Determining if patients can transition from Degarelix Acetate to other medications without a rise in testosterone levels, 2) Assessing the immune responses in the prostate gland when Degarelix Acetate is used alone or in combination with other treatments, and 3) Evaluating the safety and effectiveness of these treatment approaches.
  • How do researchers measure the effectiveness of Degarelix Acetate in these trials? Researchers use various methods to measure the effectiveness of Degarelix Acetate, including: 1) Monitoring testosterone levels over time, 2) Examining T-cell infiltration in the prostate gland after treatment, 3) Measuring prostate-specific antigen (PSA) levels, and 4) Assessing pathological responses and long-term PSA recurrence rates after surgery.

Ongoing Clinical Trials on Degarelix Acetate

  • Study on Lutetium (177Lu) Vipivotide Tetraxetan and Androgen Receptor Inhibitors for Patients with Castration-Resistant Prostate Cancer

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Czechia France Germany Italy The Netherlands Poland +1

  • Study of [225Ac]Ac-PSMA-R2 for Men with Advanced Prostate Cancer Previously Treated or Not with 177Lu-PSMA Therapy

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France

Glossary

  • Androgen Deprivation Therapy (ADT): A treatment approach for prostate cancer that aims to reduce levels of male hormones (androgens) in the body, which can stimulate the growth of prostate cancer cells.
  • Gonadotropin-releasing hormone (GnRH) receptor antagonist: A type of medication that blocks the action of GnRH in the body, leading to a decrease in the production of testosterone.
  • Testosterone: The primary male sex hormone that plays a crucial role in male development and sexual characteristics. In prostate cancer, reducing testosterone levels can help slow down or stop cancer growth.
  • Prostate-specific antigen (PSA): A protein produced by the prostate gland. Elevated PSA levels may indicate prostate cancer or other prostate conditions.
  • Neoadjuvant therapy: Treatment given before the main treatment, usually to shrink a tumor or prepare the body for the primary treatment.
  • Immunotherapy: A type of cancer treatment that helps the immune system fight cancer cells.
  • T-cells: A type of white blood cell that plays a central role in the body's immune response.
  • Radical prostatectomy: A surgical procedure to remove the entire prostate gland and surrounding tissues to treat prostate cancer.

References

  1. https://clinicaltrials.gov/study/NCT01344564
  2. https://clinicaltrials.gov/study/NCT01696877